成都圣诺生物科技股份有限公司 2025年前三季度业绩预告的自愿性披露公告

Core Viewpoint - Chengdu Saintno Biological Technology Co., Ltd. anticipates significant growth in net profit for the first three quarters of 2025, with projections indicating an increase of 100.53% to 145.10% compared to the same period last year [1][3]. Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 114.20 million yuan and 139.57 million yuan for the first three quarters of 2025, representing an increase of 57.25 million yuan to 82.63 million yuan year-on-year [1]. - The projected net profit, after deducting non-recurring gains and losses, is estimated to be between 113.35 million yuan and 138.54 million yuan, reflecting an increase of 59.70 million yuan to 84.89 million yuan year-on-year [1]. Previous Year Performance - In the same period last year, the net profit attributable to shareholders of the parent company was 56.95 million yuan, and the net profit after deducting non-recurring gains and losses was 53.66 million yuan [2]. Reasons for Performance Change - The company's main business has shown stable development, with a continuous increase in demand for its peptide raw material business, contributing to a steady rise in overall performance and maintaining strong market competitiveness and profitability [3].